6 results on '"Valerio Bonaldo"'
Search Results
2. Pharmacological inactivation of the prion protein by targeting a folding intermediate
- Author
-
Giovanni Spagnolli, Tania Massignan, Andrea Astolfi, Silvia Biggi, Marta Rigoli, Paolo Brunelli, Michela Libergoli, Alan Ianeselli, Simone Orioli, Alberto Boldrini, Luca Terruzzi, Valerio Bonaldo, Giulia Maietta, Nuria L. Lorenzo, Leticia C. Fernandez, Yaiza B. Codeseira, Laura Tosatto, Luise Linsenmeier, Beatrice Vignoli, Gianluca Petris, Dino Gasparotto, Maria Pennuto, Graziano Guella, Marco Canossa, Hermann C. Altmeppen, Graziano Lolli, Stefano Biressi, Manuel M. Pastor, Jesús R. Requena, Ines Mancini, Maria L. Barreca, Pietro Faccioli, and Emiliano Biasini
- Subjects
Biology (General) ,QH301-705.5 - Abstract
Spagnolli, Massignan, Astolfi et al. design a new drug discovery approach, termed Pharmacological Protein Inactivation by Folding Intermediate Targeting, in which folding intermediates of disease-causing proteins are targeted. They test it on the cellular prion protein, identifying ligands stabilizing a folding intermediate and consequently promoting its degradation by the cellular quality control machinery.
- Published
- 2021
- Full Text
- View/download PDF
3. Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity
- Author
-
Luisa Diomede, Sara Baroni, Ada De Luigi, Arianna Piotti, Jacopo Lucchetti, Claudia Fracasso, Luca Russo, Valerio Bonaldo, Nicolò Panini, Federica Filippini, Fabio Fiordaliso, Alessandro Corbelli, Marten Beeg, Massimo Pizzato, Francesca Caccuri, Marco Gobbi, Emiliano Biasini, Arnaldo Caruso, and Mario Salmona
- Subjects
SARS-CoV-2 ,COVID-19 ,spike protein ,tetracyclines ,doxycycline ,in vitro ,Microbiology ,QR1-502 - Abstract
The rapid spread of the pandemic caused by the SARS-CoV-2 virus has created an unusual situation, with rapid searches for compounds to interfere with the biological processes exploited by the virus. Doxycycline, with its pleiotropic effects, including anti-viral activity, has been proposed as a therapeutic candidate for COVID-19 and about twenty clinical trials have started since the beginning of the pandemic. To gain information on the activity of doxycycline against SARS-CoV-2 infection and clarify some of the conflicting clinical data published, we designed in vitro binding tests and infection studies with a pseudotyped virus expressing the spike protein, as well as a clinically isolated SARS-CoV-2 strain. Doxycycline inhibited the transduction of the pseudotyped virus in Vero E6 and HEK-293 T cells stably expressing human receptor angiotensin-converting enzyme 2 but did not affect the entry and replication of SARS-CoV-2. Although this conclusion is apparently disappointing, it is paradigmatic of an experimental approach aimed at developing an integrated multidisciplinary platform which can shed light on the mechanisms of action of potential anti-COVID-19 compounds. To avoid wasting precious time and resources, we believe very stringent experimental criteria are needed in the preclinical phase, including infectivity studies with clinically isolated SARS-CoV-2, before moving on to (futile) clinical trials.
- Published
- 2021
- Full Text
- View/download PDF
4. Characterization of Physical, Mechanical, and Biological Properties of SilkBridge Nerve Conduit after Enzymatic Hydrolysis
- Author
-
Giuliano Freddi, Emiliano Biasini, Valerio Bonaldo, Antonio Alessandrino, Silvia Biggi, Romina Belli, Daniele Peroni, Marco Biagiotti, Valentina Vincoli, and Giulia A. Bassani
- Subjects
Chemistry ,fungi ,Biochemistry (medical) ,Biomedical Engineering ,Nerve guidance conduit ,Fibroin ,General Chemistry ,Biomaterials ,Biological property ,Enzymatic hydrolysis ,Biophysics ,Degradation (geology) ,In vitro degradation ,Cytotoxicity - Abstract
The in vitro degradation profile and the cytotoxicity of the degradation products of a silk fibroin (SF)-based nerve conduit (SilkBridge), with a complex three-layered wall architecture comprising ...
- Published
- 2020
5. Astrocytic microdomains from mouse cortex gain molecular control over long-term information storage and memory retention
- Author
-
Bai Lu, Nicoletta Berardi, Beatrice Vignoli, Valerio Bonaldo, Gabriele Sansevero, Robert Blum, Spartaco Santi, Manju Sasi, Marco Canossa, Emiliano Biasini, Roberto Rimondini, Vignoli, Beatrice, Sansevero, Gabriele, Sasi, Manju, Rimondini, Roberto, Blum, Robert, Bonaldo, Valerio, Biasini, Emiliano, Santi, Spartaco, Berardi, Nicoletta, Lu, Bai, and Canossa, Marco
- Subjects
Receptor complex ,neurotrophic factors ,QH301-705.5 ,Information storage ,Long-Term Potentiation ,Medicine (miscellaneous) ,Nerve Tissue Proteins ,Receptors, Cell Surface ,Tropomyosin receptor kinase B ,long-term information storage ,Article ,Long-term memory ,General Biochemistry, Genetics and Molecular Biology ,Mice ,Memory ,Neurotrophic factors ,Animals ,Biology (General) ,mouse ,Astrocytic ,Membrane Glycoproteins ,Chemistry ,microdomain ,Brain-Derived Neurotrophic Factor ,Long-term potentiation ,Memory retention ,Protein-Tyrosine Kinases ,memory retention ,BDNF ,Astrocytes ,Phosphorylation ,Memory consolidation ,Astrocyte ,General Agricultural and Biological Sciences ,Neuroscience - Abstract
Memory consolidation requires astrocytic microdomains for protein recycling; but whether this lays a mechanistic foundation for long-term information storage remains enigmatic. Here we demonstrate that persistent synaptic strengthening invited astrocytic microdomains to convert initially internalized (pro)-brain-derived neurotrophic factor (proBDNF) into active prodomain (BDNFpro) and mature BDNF (mBDNF) for synaptic re-use. While mBDNF activates TrkB, we uncovered a previously unsuspected function for the cleaved BDNFpro, which increases TrkB/SorCS2 receptor complex at post-synaptic sites. Astrocytic BDNFpro release reinforced TrkB phosphorylation to sustain long-term synaptic potentiation and to retain memory in the novel object recognition behavioral test. Thus, the switch from one inactive state to a multi-functional one of the proBDNF provides post-synaptic changes that survive the initial activation. This molecular asset confines local information storage in astrocytic microdomains to selectively support memory circuits., Beatrice Vignoli et al. examine potential molecular mechanisms of long-term storage information in mice. Their results suggest that astrocytes may help convert neuronal BDNF precursor into active prodomain and mature forms to enhance post-synaptic signaling and memory, providing further insight into the development of memory circuits.
- Published
- 2021
6. Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity
- Author
-
Arianna Piotti, Federica Filippini, Luisa Diomede, Alessandro Corbelli, Massimo Pizzato, Fabio Fiordaliso, Jacopo Lucchetti, Sara Baroni, Ada De Luigi, Francesca Caccuri, Mario Salmona, Marten Beeg, Arnaldo Caruso, Valerio Bonaldo, Nicolò Panini, Claudia Fracasso, Luca Russo, Marco Gobbi, and Emiliano Biasini
- Subjects
viruses ,Virus Replication ,spike protein ,Transduction (genetics) ,Transduction, Genetic ,Chlorocebus aethiops ,Medicine ,Receptor ,Doxycycline ,Infectivity ,COVID-19 ,In vitro ,SARS-CoV-2 ,Spike protein ,Surface plasmon resonance ,Tetracyclines ,Angiotensin-Converting Enzyme 2 ,Animals ,Cell Cycle ,HEK293 Cells ,Humans ,Protein Binding ,Spike Glycoprotein, Coronavirus ,Vero Cells ,Virus Physiological Phenomena ,Host-Pathogen Interactions ,in vitro ,Cell cycle ,tetracyclines ,doxycycline ,surface plasmon resonance ,QR1-502 ,Spike Glycoprotein ,Infectious Diseases ,medicine.drug ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Biology ,Microbiology ,Virus ,Article ,Transduction ,Genetic ,Virology ,business.industry ,HEK 293 cells ,Clinical trial ,Coronavirus ,Vero cell ,business - Abstract
The pandemic caused by the SARS-CoV-2 has created the need of compounds able to interfere with the biological processes exploited by the virus. Doxycycline, with its pleiotropic effects, including anti-viral activity, has been proposed as a therapeutic candidate for COVID-19 and about twenty clinical trials have started since the beginning of the pandemic.To gain information on the activity of doxycycline against SARS-CoV-2 infection and clarify some of the conflicting clinical data published, we designed in vitro binding tests and infection studies with a pseudotyped virus expressing the spike protein, as well as a clinically isolated SARS-CoV-2 strain. Doxycycline inhibited the transduction of the pseudotyped virus in Vero E6 and HEK-293 T cells stably expressing human receptor angiotensin-converting enzyme 2 but did not affect the entry and replication of SARS-CoV-2.Although this conclusion is apparently disappointing, it is paradigmatic of an experimental approach aimed at developing an integrated multidisciplinary platform. To avoid wasting precious time and resources we believe very stringent experimental criteria are needed in the preclinical phase, including infectious studies with SARS-CoV-2 in the platform before moving on to [failed] clinical trials.Author SummaryThe pandemic caused by the SARS-CoV-2 virus has created a completely unusual situation in rapidly searching for compounds able to interfere with the biological processes exploited by the virus. This new scenario has substantially changed the timing of drug development which has also resulted in the generation of controversial results, proving that the transition from computational screening to the clinical application requires great caution and careful studies. It is therefore necessary to establish new paradigms for evaluating the efficacy of a potential active molecule.We set up a preclinical platform aimed at identifying molecules active against SARS-CoV-2 infection developing a multidisciplinary approach based on very stringent experimental criteria, comprising in-silico studies, in vitro binding tests and infection studies with pseudovirus expressing the spike protein as well as clinically isolated SARS-CoV-2 strains. We focused our attention on doxycycline which has been suggested as potential therapeutic candidate for treating COVID-19 and is currently employed in about twenty clinical trials. Doxycycline resulted effective in inhibiting the transduction of pseudovirus but it did not affect the entry and replication of SARS-CoV-2. The results obtained underline the need to define more stringent and controlled pharmacological approaches before wasting precious time and resources with clinical trials.
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.